MBM-55S

TargetMol
Product Code: TAR-T11961
Supplier: TargetMol
CodeSizePrice
TAR-T11961-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11961-2mg2mg£306.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11961-5mg5mg£431.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11961-10mg10mg£600.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11961-1mL1 mL * 10 mM (in DMSO)£603.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11961-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11961-50mg50mg£1,187.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11961-100mg100mg£1,581.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11961-500mg500mg£3,107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer cells. MBM-55S shows antitumor activities.
CAS:
2083624-07-9
Formula:
C36H39FN6O10
Molecular Weight:
734.73
Pathway:
PI3K/Akt/mTOR signaling; Angiogenesis; Tyrosine Kinase/Adaptors; Stem Cells; MAPK; Cell Cycle/Checkpoint; Cytoskeletal Signaling; Chromatin/Epigenetic
Purity:
0.98
SMILES:
O=C(CCC(O)=O)O.O=C(C1=C(OCC2=CC(F)=CC=C2)C=C(C3=CN=C4C=C(C5=CN(CCN(C)C)N=C5)C=CN43)C=C1)N.O=C(CCC(O)=O)O
Target:
GSK-3; MAPK; Akt; Bcr-Abl; CDK; S6 Kinase; Aurora Kinase

References

1. Xi JB, et al. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. Eur J Med Chem. 2017 Jan 27;126:1083-1106.